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Abstract 
 
Ovarian cancer is the fifth deadliest cancer in woman, and epithelial malignancies account for 90% of cases. 
Tumor recurrence after chemotherapy or radiation remains a major obstacle to successful ovarian cancer 
treatment. Despite the large number of studies, molecular events that govern the emergence of aggressive 
therapy-resistant cells after chemotherapy are poorly defined. Genetic modifications, such as copy number 
variation (CNV), play an important role in controlling the expression of genes that are involved in chemo 
resistance. We analyzed CNV data that is publically available through the Cancer Genome Atlas and others. Of 
particular interest was the transcription factor HIF1α which plays an integral role in oxidative stress response 
such as those induced by chemotherapy reagents? The present study provides evidence for the rare escape of 
tumor cells from drug-induced cell death by entering a non-cycling senescent state. We report the adaptive 
response of human ovarian surface epithelium cells to CoCl2, a chemical hypoxia-mimicking agent resulting in a 
senescent-like state of chemo resistant cells. The effect of the treatment was evaluated on CNV of HIF-1α gene 
expression, cell proliferation, survival, and tumor invasiveness.  
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We show here that CNV duplication events of HIF1α results in an oxidative stress response in cells leading to 
chemo resistance through the induction of cellular senescence. Understanding the molecular events associated 
with chemo resistance will ultimately lead to better patient treatment and outcomes. 
  
Key-words: HIF1α, copy number variationylation, epithelial ovarian cancer, apoptosis, chemo resistance, 
senescence. 
 
 
1. Introduction 
 
Epithelial ovarian cancer is the fifth leading cause of cancer death among women in the United States, accounting 
for 5% of cancer deaths (Jemal et al., 2011). Though rare, most patients are diagnosed with advanced disease due 
to the non-specific nature of early symptoms and lack of effective screening strategies. For the approximate 75% 
of women diagnosed with stage III or IV disease, the likelihood of long term disease-free survival ranges from 15 
to 20% (Hoskins et al., 1991; McGuire et al., 2003; Barnholtz-Sloan et al., 2003). Early screening is difficult 
because obvious signs and symptoms such as pelvic pain, as cites or problems urinating, do not present until after 
the tumors have progressed to advanced stages.  
 
Despite the recent advances in chemotherapy drugs, the survival rate for ovarian cancer is still very low due to the 
high rate of relapse with cancer cells that are resistant to chemotherapeutic drugs. Current treatments of 
chemotherapy utilize a combination of platinum drug and a taxane drug. Platinum induces apoptosis, while the 
taxane interferes with cell division (Barnholtz-Sloan et al., 2003). Although initial treatment is effective, all 
patients that experience relapse display chemo resistant tumors (Jemal et al., 2011). This requires more aggressive 
therapies to be used, which take a larger toll on the patient, and are less effective at treating the tumors (McGuire 
et al., 2003). 
 
Researchers have been trying to discover the mechanisms, which cause these initially sensitive tumors to develop 
resistance. DNA copy number variation (CNV) is one such mechanism that shows promise3. CNV is a frequent, 
dynamic and complex form of genetic diversity, where in which copy number differences are observed between 
two or more genomes (Feuk L, 2006). CNVs are larger than 1 kilobase (kb) in size and involve gains or losses of 
genomic DNA. Recently, these genomic rearrangements have been linked to a variety of diseases with the 
resulting deletion or duplication events that take place in the cell (Sebat J, 2004). CNVs occur commonly in the 
genome and have been implicated in risk of complex diseases including schizophrenia (Need et al., 2009), 
neuroblastoma (Diskin et al., 2009), and prostate cancer (Lawrence et al., 2008; Liu et al., 2009). With the advent 
of large-scale computer information processing, it is now possible to analyze CNV on a genomic level. The 
analysis performed by the Cancer Genome Atlas (TCGA) and other groups has revealed great insights in ovarian 
cancer genomic alterations allowing us to compare the genomes of sensitive tumors with those that are resistant. 
Genomic duplication and micro deletion events were frequent throughout the genome. Of specific interest were 
genes involved in transcription regulation, including MYC and HIF1α (Bell D, 2011).  
 
HIF-1 is the major transcription factor involved in the adaptive response to hypoxia and consists of HIF-1 alpha 
and HIF-1 beta subunits. HIF1α plays a crucial role in the transcription of many genes, including those involved 
in oxygen homeostasis, glucose uptake within cells, angiogenesis, and both pro and anti-apoptotic actions 
(Donghoon Y et al., 2006; Carmeliet P, 1998; Yu EZ et al., 2004). Studies have shown that hypoxia, oxygen 
concentration is less than the physiological minimum required for the cell, can induce mitotic arrest. The 
minimum oxygen concentration necessary for a cell varies in different areas of the body. HIF-1 is a gene that 
regulates the homeostatic response to hypoxia. Additionally, hypoxia has the ability to induce cellular senescence. 
Cellular senescence is a programmed response to remove cells with damaged DNA from the proliferative 
population as they age. Senescence can be induced by telomere shortening, DNA damage, or oncogene activity. 
At the ends of every strand of DNA are telomeres, non coding regions of DNA that protect the coding regions 
from being lost due to replication. After each replication the telomeres become shorter. When the telomeres 
become too short, cells undergo senescence in order to prevent the proliferation of cells with damaged DNA (Yu 
EZ et al., 2004). One way the human body tries to prevent the proliferation of cancerous cells is a pathway known 
as cellular senescence. Cellular senescence is one of the most fundamental aspects of cell behavior, and is thought 
to play a crucial role in regulating cellular lifespan both in vitro and in vivo.  
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Moreover, tumor hypoxia induces cellular senescence and increases the resistance of cancer cells to chemotherapy 
(Yu EZ et al., 2004). Hypoxia-inducible factor-1α (HIF-1α) is the main transcriptional factor activated by hypoxia 
and it plays a key role in reprogramming tumor growth.  
 
In this paper, we aimed to determine how CNV through duplication of the gene HIF1α plays role in chemo 
resistance of ovarian cancer. Our functional analysis screen has revealed the activation of the cellular senescence 
pathway in human ovarian surface epithelial (HOSE). In order to study the effects of hypoxia in vitro we used 
medium infused with 50 µM CoCl2 and studied the effects of it on HIF-1α gene expression at protein levels. In this 
paper we determined that CNV duplication of HIF1α induced by hypoxic events induces senescence in HOSE 
cells. Our study indicates that oxidative stress caused by chemotherapeutic agents generates senescent-like cells 
which play an important role in tumor chemo resistance. We suggest that premature senescence is a mechanism of 
tumor suppression.  
 
2. Methods 
 
2.1 Materials  
 
HOSE 6-3, a normal human ovarian surface epithelial cell line that has been immortalized by HPV E6/7 ORF 
(obtained from Dr. S. W. Tsao, Cold Spring Harbor Laboratory, and NY) cell line was used to study ovarian 
cancer proliferation. All cell lines were maintained in DMEM 10% fetal bovine serum. SYBR Green I fluorescent 
dye, reverse transcriptase and RNase inhibitor was purchased from Applied Biosystems, Foster City, CA. 
Antibodies were obtained from Cell Signaling. The Western Lightning ECL-plus detection system was obtained 
from Perkin Elmer. Trans well assays and reagents were obtained from BD Bioscience. RNEasy, DNEasy 
obtained from Qiagen. Cisplatin and Carboplatin were purchased from Sigma. Primers were supplied by Sigma 
Genosys. Cell counting kit-8 was purchased from Dojindo Molecular Technologies, Inc. Neutral red dye uptake 
was purchased from Sigma. MTT viability assay kit was supplied by Roche 
 
2.2 Cell Proliferation Assay 
 
Cells were seeded into 6-well plates at 10,000 cells/mL in DMEM supplemented with 10% FBS, 1% L-glutamine, 
1% penicillin-streptomycin from Invitrogen. Cells were weashed in PBS, trypsinized in and counted using a 1:1 
0.4% trypan blue solution every three days for growth and viability analysis. Viable cells with no blue stain and 
dead cells with blue stain were counted using a hemocytometer. Proliferation and metabolic activity was 
determined using alamar Blue dye assay and spectrophotmetry using the Biotek EL800 at 600nm. 
 
2.3 Chemotherapy Sensitivity and Survival 
 
The ovarian cell line HOSE was tested for IC20, IC50 and IC80 carboplatin sensitivity levels. Cells were seeded 
at 10^3cells/well in a 96 well plate and treated with carboplatin at a concentration range of 1–100 µg/ml in 100 µl 
of fully supplemented DMEM. After a period of 72 h cytotoxicity was assessed by trypan blue dye exclusion 
viability assay using 1:100 dilutions in cell culture suspensions. Additionally, the CCK-8 assay was used to 
measure cell survival after treatment with drugs following the manufacturer’s protocol and absorbance measured 
at 450 nm using the Biotek EL800 spectrophotometer. 
 
2.4 Colorimetric Caspase - 3 Apoptosis Assay 
 
The caspase 3 Assay Kit (Colorimetric) (ab39401) was used according to the manufacturer’s instructions. It is an 
assay to measure the activity of caspases using spectrophotometric detection. Briefly, cell lysates were prepared 
after treatment with carboplatin in Hose +HIF1α and Hose control. Samples were treated with 2X reaction 
buffer/DTT and DEVD-pNA. After 2 hours incubation at 37°C, results were read at 405-nm using the Biotek 
EL800 spectrophotometer. Comparison of triplicate plates using the absorbance of p-NA from our +HIF1α treated 
samples and our control was used to determine the fold increase in caspase 3 activity. 
 
2.4 Cell treatment 
 
Exponential-phase ovarian cancer cells were plated into 6-well plates and allowed to adhere for at least 24 h. 
When the cell density reached approximately 75%, the cells were treated with 10 µg previously cloned human 
HIF-1α cDNA fragment encoding amino acids 432–528 in a pGEX2T vector using Lipofectamine following the 
manufacturer’s instructions (Invitrogen). Non-targeting cDNA was obtained from Invitrogen and used as our 
control. 
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2.5 MTT Assay 
 
MTT assays (Mosmann, 1983; Hansen et al., 1989) were used to quantify cell number/density of viable cells by, 
introduction of 1mg/ml of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide to 1x103 cells and 
incubation for 4h at 37°C. One volume of 20% SDS, 50% N, N-dimethylformamide was added and the plates 
were incubated overnight at 37°C. The level of Formazan, the metabolite of MTT was measured at 600 nm using 
the Biotek EL800 spectrophotometer and means of the triplicates were calculated. Following non-cellular 
background subtraction, all data were normalized to the MTT conversion activity of solvent-treated control cells.  
 
2.6 Chemotherapy Sensitivity and Survival 
 
The ovarian cell lines HOSE 6-3 was tested for Carboplatin and Doxorubicin sensitivity to determine the IC20, 
IC50 and IC80 values. Briefly, the cell line was treated with either chemotherapy drug at a concentration range of 
1-100ug/ml in 100ul of fully supplemented DMEM. After a period of 72 hrs the drug was aspirated and 
proliferation was assessed by MTT assay. The Hose 6-3 CoCl2 or PBS control treated cells were challenged with 
the IC50 dose of chemotherapy reagent. The cell line was seeded at 103 cells per well in a 96 well plate and 
subjected to a 72 hour treatment followed by a 72 hour recovery period. After treatment the cell proliferation was 
assessed by MTT assay, Netral Rerd Dye Uptake, and CKK-8 following the manufacturer’s instructions.  
 
2.7 Real-time qPCR 
 
Total cellular RNA was isolated using RNeasy kit and 1ug of RNA was reverse transcribed to cDNA using the 
Super Script One Step RT-PCR system by Invitrogen, according to the manufacturer’s instructions. cDNA at a 
1:10 dilution was used for all PCR reactions and primers were designed by Sigma. Primer sequences are as 
follows: HIF1α (5’ 
 
ACTB (5’-TTGCCGACAGGATGCAGAAGGA-3’ and 5’-AGGTGGACAGCGAGGCCAGGAT-3’). All PCR 
reactions were performed on CFX-96 Bio-Rad RT System in triplicate and validated by the presence of a single 
peak in the melt curve analysis. Changes in gene expression were calculated relative to the actin control.  
 
2.7 Immunoblotting. 
 
Samples were harvested, total protein extracted and protein concentration determined using the Bradford Assay. 
Western blotting was performed using 5–10 µg of protein lysates and electrophoresis with the Invitrogen E-Page® 
system. After transfer of lysates from gel to PVDF membrane, blots were blocked and hybridized for 
immunodetection using anti-rabbit monoclonal antibody against HIF1α, diluted 1:1,000 overnight, followed by 
incubation with anti-rabbit secondary antibody (horseradish peroxidase HRP-conjugated), diluted 1:10,000. 
Membranes were washed in TBS-Tween at room temperature. Anti-rabbit monoclonal β tubulin was used as a 
loading control. Membranes were washed and protected from light. The Western Lightning ECL-plus (Perkin 
Elmer) was used for signal detection. NIH Image J software was used to quantitate intensity values for protein 
levels. 
 
2.8 Senescence 
 
Senescence induced by HIF1α were stained using Millipore’s senescence-associated -galactosidase (SA--gal) 
assay following the manufacturers protocol. After 72 hour treatment with carboplatin, cells were washed 1x with 
phosphate buffered saline, fixed in a 1x fixative (provided) and stained using a freshly prepared and protected 
from light SA-βgal solution. Next, the plates were wrapped in aluminum foil to protect them from light and were 
placed in an incubator at 37C and 5% CO2 for 48 hours. The cells were removed from the incubator and the stain 
was aspirated off the plates. Cells that were stained for senescence-associated -galactosidase activity were 
stained blue under standard light microscopy. The percentage of positively blue stained cells was determined by 
scoring six random high power fields per well in a 6-well plate.  
 
2.9 Wound Healing Assay 
 
Cell migration was assessed by the ability of the cells to migrate into a cell-free area. Briefly, cells were plated 1 
× 105 cells in full growth medium on 6-well plates and grown for 24 h to reach confluence. The monolayers were 
then wounded by scratching with a plastic yellow pipette tip. After washing, the cells were incubated in growth 
medium for 12-16hrs and observed under a microscope. The wound closure was estimated as the ratio of the 
remaining wound area relative to the initial wounded area using Image J software. Experiments were repeated at 
least three times. 
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2.10 Cellular Invasion 
 
Invasive cells are able to move through an extracellular matrix into neighboring tissues. Cellular invasion can be 
measured in vitro using a Boyden chamber. Briefly, 2.5 x 10^4 serum starved cells are seeded in the top of the 
insert in serum-free media, while serum acts as chemo attractant and is placed in the well below. Migratory cells 
move through the pores toward the chemo attractant below. Cells that had invaded to lower surface of the 
Matrigel-coated membrane were fixed with 4% methanol in PBS, stained with 1:1 dilution of crystal violet, and 
counted in five random fields using a bright field microscope. The number of invading cells was quantified and 
normalized to controls.  
 
2.11 Transformation Assay 
 
The Millipore Cellular transformation Kit was used to determine transformation of our low passage HOSE cells. 
Cells were seeded at 1.25 × 105 cells per well in 6-well dishes with or without transfection of HIF1α according to 
the manufacturer's protocols. Two days later, the cells were transferred to 10 cm plates. After reaching 
confluence, they were kept for 21 days in DMEM containing 7% calf serum, after which they were stained with 
0.5% crystal violet. Quantitation plotted is the means and standard errors of duplicate assays and is representative 
of at least six experiments. 
 
2.12 Statistical analysis 
 
The statistical significance of the differences in data between each treatment groups was determined by applying 
Student's t-test. A P-value 0.05 was considered significant. Unless otherwise noted, experiments were repeated 
three times with up to 10 replicates per trial. 
 
3. Results 
 
3.1 Gene Candidate Selections 
 
Hypoxia, frequently found in the center of solid tumors, is a major obstacle in the development of effective cancer 
chemotherapy. We hypothesized that tumors have taken advantage of molecular mechanisms to increase 
transcription of genes resulting in resistance to platinum treatment. We have used the variable, platinum 
resistance, clinically defined as tumor growth 6 months or less after treatment ceases. To identify DNA CNV 
changes we utilized publically available data from TCGA using representational oligonucleiotide microarray 
analysis (ROMA). We performed statistical tests to identify genes that when expression has changed can 
segregate sensitive from resistant patients. The CNV data was then associated with available expression data to 
identify which genes are significantly up regulated and oncogenic or down regulated and suppressive (Table 1).  
 
Common amplifications encoded CCNE1, MYC, and HIF1, while common deletions included BRCA1 and TP53 
(Bolton et al., 2012). We identified HIF1α among the top 10 genes associating with resistance when expression 
levels are up regulated. HIF1α is a basic helix-loop-helix subunit of the heterodimeric transcription factor 
hypoxia-inducible factor 1. HIF1α has been observed to play a role in chemo resistance of several tumors, 
including gastric (Liu L, 2007). Genes predicted to have high expression correlations will allow us to better 
determine which functions are potentially altered in tumor samples. Furthermore, uncommon focal amplifications 
were seen in the HIF1 transcriptional regulator, therefore making it an unusal candidate to select for further 
analysis (Fig 1B).  
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Table 1: Significantly mutated genes in Ovarian Cancer 
 
Gene Chromosome Gene Name Function Summary 
BRCA1 17 breast cancer 1, early 
onset 
BRCA1 is a tumor suppressor involved in pathways such as DNA 
damage repair, ubiquitination and transcriptional regulation to maintain 
genomic stability. Required for appropriate cell cycle arrests in both the 
S-phase and the G2 phase of the cell cycle.  
BRCA2 13 breast cancer 2, early 
onset 
Involved in double-strand break repair and/or homologous recombination. 
May participate in S phase checkpoint activation. 
CCNE1 19 Cyclin E1 Regulates G1 to S transition of the cell cycle; over expressed in many 
tumors leading to a deregulated levels of protein and kinase activity 
relative to the cell cycle and inducing chromosome instability 
CDK12 17 Cdc2-related kinase, 
arginine/serine-rich 
Involved in RNA splicing. 
 
CSMD3 8 CUB And Sushi 
Multiple Domains 3 
Protein Coding gene. Diseases associated with CSMD3 include certain 
forms of epilepsy. An important paralog of this gene is CR1L. 
FAT3 11 FAT Atypical 
Cadherin 3 
May play a role in the interactions between neurites derived from specific 
subsets of neurons during development 
GABRA6 5 gamma-aminobutyric 
acid (GABA) A 
receptor, alpha 6 
GABA, the major inhibitory neurotransmitter in the vertebrate brain, 
mediates neuronal inhibition by binding to the GABA/benzodiazepine 
receptor and opening an integral chloride channel. 
HIF1α 14 Hypoxia inducible 
factor 1, alpha 
Functions as a master transcriptional regulator of the adaptive response to 
hypoxia. 
MYC 8 Avian 
Myelocytomatosis 
Viral Oncogene 
Homolog 
Transcription factor and oncogene, erythropoietin early response gene, 
interacting with various cellular factors including MAX, YY1, AMPHL. 
Important for stimulating genes required for proliferation; induces 
apoptosis in sensitive cells 
NF1 17 Neuro fibromin 1 Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras 
GAP, but lower specific activity. May be a regulator of Ras activity. 
RB1 13 retinoblastoma 1 Key regulator of entry into cell division that acts as a tumor suppressor. 
Acts as a transcription repressor of E2F1 target genes.  
TP53 17 tumor protein p53 Acts as a tumor suppressor in many tumor types; induces growth arrest or 
apoptosis depending on the physiological circumstances and cell type. 
Involved in cell cycle regulation as a trans-activator that acts to 
negatively regulate cell division by controlling a set of genes required for 
this process.  
 
Table 1: Selected ovarian cancer genes selected based off statistical analysis of TCGA data and expression 
analysis. Genes highlighted in red are up regulated and genes highlighted in green are down regulated. 
 
3.2 In Vitro Platinum Screen 
 
It was unclear if our gene candidate identified functionally from our bioinformatics analysis altered platinum 
resistance in the cell. Thus we performed an in vitro carboplatin resistance assay. HOSE 6–3 (onward, will be 
referred to as HOSE) was selected to perform functional studies. HOSE is a normal human ovarian surface 
epithelial cell line that has been immortalized by introduction of the HPV E6/7 ORF. This cell line has been 
previously used in the study of chemoresistance (Siu et al., 2012) and has been found to be sensitive to 
carboplatin treatment.  
 
We were most interested in genes that were had altered CNV and were transcriptionally amplified. Table 1 lists 
our top candidates for cDNA transfection selection. The induction of transcription caused by CNV was modeled 
by the introduction of cDNA clones. Since we several candidates and only could test for one at a time, we chose 
to further validate HIF1α for this study. To be more confident of our candidate, each cDNA clone was 
individually verified for carboplatin resistance using three concentrations of carboplatin, the IC20, the IC50, and 
the IC80. Fig 1A illustrates the basic experimental design.  
 
 
 
 
 
 
 
 
American International Journal of Contemporary Research                                           Vol. 6, No. 5; October 2016 
 
7 
A.  
 
B. 
Fig 1: Schematic representation of experimental plan and tumor analysis. (A) Part one consisted of a 
bioinformatic analysis of publically available data on The Cancer Genome Atlas and Genome Wide Association 
Studies databases. Next, we performed an in-vitro carboplatin screen. Finally, various functional tests were done 
to understand chemoresistance mechanisms. (B) Kaplan–Meier plot showing the segregation between 
carboplatin therapy resistant and sensitive patient groups on the genomic segment surrounding HIF1α. The lines 
represent loss, gain, and normal copy number for HIF1α.  
 
3.3 Increased Expression of HIF1α Induces Platinum Resistance 
 
We went on to study the effect of HIF1α amplification on carboplatin resistance using our in vitro cell culture 
model to further validate our screening methodology. The homeostatic response to hypoxia is mediated by this 
gene and it has already been correlated with poor survival in several studies (Braicu et al., 2014, and Lu et al., 
2010). Its expression is amplified in a number of other solid tumors (Zhong et al., 1999).   
Cells infected with HIF1α cDNA were assayed by qPCR and Western blot to ensure efficient amplification of 
HIF1α expression levels (Fig 2A, Fig 2B). Our results indicate that after IC50 dose treatment of carboplatin, 
induction of HIF1α expression resulted in a survival advantage (Fig 2C). As it is a transcription factor, 
amplification of HIF1α expression may increase carboplatin resistance by up regulating several genes important 
in survival, thus increasing cell growth and increasing the number of cells surviving treatment. To address this 
concern, growth assays were done over the course of 9 days without the addition of carboplatin, demonstrating 
that amplification of HIF1α expression in HOSE cell lines had a moderate effect on the number of cells growing 
(Fig 2C). A 3-day Bromodeoxyuridine (BrdU) assay was also used to measure the level of actively dividing cells. 
The BrdU assay exhibited a selective growth advantage for HIF1α amplified cells when compared to their control 
counterparts in the HOSE cell lines. This result was statistically significant, p<0.05. 
 
 
 
 
HIF1α CNV 
 
 --  
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A  B      
 
 
 
C    
 
Fig 2: Expression and Growth Summary Analysis for HIF1α. 
 
(A) RNA was prepared separately from each sample cell line with either cDNA over expression of HIF1α and 
MYC, or knockdown using siRNA for TP53. qPCR analysis was performed for each sample and the data 
combined. Data was normalized to housekeeping gene, Actin (Ctrl). Error bars indicate the standard error of the 
mean after three independent trials (s.e.m.). Statistical analysis by t-test. (B) Western blot was used to determine 
translational activity of HIF1α, with Actin as the control antibody. Lane indicated with + includes the cDNA for 
HIF1α whereas the – indicates lysates with no transfection. (C) Effects of +HIF1α on cell proliferation according 
to BrdU incorporation assays. HOSE cells were incubated with IC50 carboplatin for 72 h. The data are the mean ± 
SD (n=3. Data represents three independent experiments, with three replicates per trial. 
 
3.4 Amplification of HIF1α expression Modulates Apoptosis through Caspase-3 Activity 
 
An alternative role for HIF1α in carboplatin resistance could be an effect on apoptosis. The deregulation of the 
apoptotic pathway is often shown to be involved in resistance (Fojo et al., 2001 and Morrison et al., 2011), and 
this process can also be epigenetically deregulated (Balch et al., 2010). To determine if HIF1α uses apoptosis to 
induce carboplatin resistance, we plated HOSE control and HOSE +HIF1α cell lines with and without 
carboplatin. After 72 hours, the percent viable cells to dead cells were determined using trypan blue stain 
exclusion from live cells as well as CCK-8 (cell counting kit-8), which determines cell viability in cell 
proliferation and cytotoxicity assays. The results showed fewer dead cells in the +HIF1α cell line compared to the 
control HOSE cell line in the presence of carboplatin (Fig 3A).  
 
To determine if any markers of apoptosis are affected by the loss +HIF1α, levels of activated caspase 3 were 
measured using western blot (data not shown), qPCR, and colorimetric enzymatic analysis. The caspase family of 
cysteine proteases plays a key role in apoptosis. Caspase 3 is synthesized as an inactive pro-enzyme that is 
processed in cells undergoing apoptosis and can be cleaved and activated by upstream caspase 8/9 targets. This 
cleavage activates the enzyme and can be readily detected in vitro. Our results indicate suppression of gene 
expression, protein expression, and enzymatic activity of Caspase 3 (Fig 3B) in +HIF1α cells when compared to 
control cell line. These results suggest that aberrant apoptosis signals are a factor in how +HIF1α CNV confers 
resistance to carboplatin. 
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A      B 
 
 
 
Figure 3: Cytotxicity, cellular proliferation, and Caspase 3 activity measurement. (A) After treatment with 
carboplatin and etoposide (control), cells containing HIF1α convey increased survival to chemotherapy treatment. 
(B) Caspase 3 apoptotic activity was measured and HOSE cells treated with either carboplatin or etoposide 
indicated increased caspase 3 activity compared to the HOSE +HIF1α. (C) These results were confirmed with 
qPCR for Caspase 3 expression. 
 
3.5 +HIF1α Induced Cells Results in Increased Senescence  
 
Tumor cells have the ability to maintain viability following chemotherapeutic exposure by undergoing alternative 
cellular fates such as cellular senescence. Tumor environmental stresses such as starvation, hypoxia and DNA 
damage induced by chemotherapy drugs have been shown to induce such fates as senescence (Saab, 2010) and it 
has been shown to be significantly associated with cancer cell survival and chemoresistance (Watson et al., 2009). 
Furthermore, senescent cells adopt a flat enlarged morphology and cease proliferation at subconfluent densities 
despite the presence of serum (reviewed by Votja, 1995). An increasingly important function of p53 is to monitor 
the genome to determine whether or not a cell is viable to enter the proliferative population. In tumor cells, 
oncogenic activation has the ability to suppress its function or can delete the gene altogether. Low levels of p53 
become more prominent following DNA damage, certain oncogenic insults, hypoxia, and a variety of other 
cellular stresses (reviewed by Ko and Prives, 1996). Activation of p53 prevents cell proliferation by inducing cell-
cycle arrest or apoptosis. To further explore whether the observed decreased cell death in the +HIF1α knockdown 
was due to protection from senescence or changes in p53 status, we performed the Millipore Cellular Senescence 
Assay and an ELISA for p53 quantification. According to our results of the SA- βgal assay, compared to control 
HOSE cells, +HIF1α Hose cells stained moderately more positive for SA-βgal after 72 hours carboplatin 
treatment (Fig 4A). Additionally, the quantitative analysis of p53 status demonstrates a no change in p53 amounts 
in the HOSE +HIF1α cells after treatment with carboplatin.  
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Figure 4: Senescent features of HOSE cells. (A) Representative image of HOSE (i) and HOSE +HIF1α (ii) cells 
after treatment for 72 hours carboplatin. (B) Changes in p53 quantification were measured using ELISA. As you 
can see from the graph, there was no significant difference in p53 amounts between HOSE and HOSE +HIF1α 
cell lines treated with or without carboplatin. 
 
3.6 HIF1α Induction Confers an Invasive and Tumorigenic Phenotype in Vitro 
 
In addition to its role in affecting apoptosis and senescence to confer carboplatin resistance, HIF1α is also a 
known transcription factor that is a major regulator of cell adaptation to hypoxic stress and plays a critical role in 
on cogenesis and angiogenesis (Birner et al., 2001). Therefore, we decided to explore whether HIF1α displayed 
these oncogenic properties in ovarian cancer in culture. To measure tumorigenicity, we first assayed whether cell 
lines with the +HIF1α required a basement membrane, and performed experiments for growth in soft agar. After 
3 weeks of growth, +HIF1α cells when compared to the control cell lines indicated no change in colony growth in 
both size and number (results not shown). In addition, a Matrigel assay was used to quantify invasive potential of 
the cells. After 36 h there was a marked increase in the number of cells invading when +HIF1α was induced 
compared to the control cells (Fig 6B). In addition, a scratch assay was also performed to evaluate migratory 
potential. In comparison to the control cell lines, we observed that the Hose cells harboring the HIF1α cDNA had 
an increased migration (Fig 6A). Collectively, these results suggest that in ovarian cancer cells, a increase in the 
level of HIF1α is associated with oncogenic features, such as increased invasiveness and tumorigenicity.  
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Figure 6: Cell migration/wound healing assay (A) Transwell cell invasion assay (B) were done using Hose 6-3 
cancer cells at 0 and 24 h, in the presence of HIF1α over expression results in a more tumorgenic phenotype. A/Bi 
and A/Biii represent HOSE control and A/Bii and A/Biv represent HOSE +HIF1α.  
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4. Discussion 
 
The effect of hypoxia on proliferation and tumor genesis has been well documented in the context of immortal 
cell lines (Votja, 1995). However, the analysis of the role hypoxia inducible factor 1-alpha plays in this pathway 
to confer resistance to drug treatment has yet to be established. As drug resistance is one of the major barriers to 
the successful treatment of malignancies, investigation of the mechanisms of drug resistance and approaches to 
overcoming it has been widely performed in the past decades. Ovarian cancer is a common cancer in women and 
the most lethal gynecologic malignancy. The high mortality rate is attributable to the asymptomatic nature of the 
early stage of the disease, the lack of reliable screening tests, and the development of drug resistance. While over 
expression of genes is crucial for control of normal cell growth and is a hallmark of cancer, it also has the 
potential to affect how tumors respond to chemotherapy (Hanahan, 2011). We have studied the genome of ovarian 
cancer to identify genes activated by DNA CNV and demonstrate that activation of the hypoxia induced factor, 
HIF1α functionally increases resistance to platinum drugs. To our knowledge, this is the first time this molecular 
signature of the gene has been implicated in therapy response.  
 
Single nucleotide polymorphisms GWASs have yielded great insights into the etiology several complex diseases 
including ovarian cancer (Song et al., 2009; Bolton et al., 2010). With much unexplained variation in ovarian 
cancer outcome, investigation of additional inherited factors remains warranted. Here, in the first germ line 
ovarian cancer CNV analysis, we have harnessed CNV data gleaned from dense genome-wide SNP genotyping in 
order to address the hypothesis that copy number variation is associated with survival.  
 
Our results indicate an increased presence of SA- βgal activity in the +HIF1a cells. SA- βgal is a protein that is 
activated in senescent cells. This indicates that the over expression of HIF1a leads to a higher rate of cells induced 
into senescence. We also found a higher survival percentage in the cells that exhibited an over expression of 
HIF1a. To determine whether the increased survivability was due to +HIF1a and not a change in p53 activity we 
performed a p53 quantification assay along with the senescence assay. The results showed there was no difference 
in p53 activity between both cell lines. From these results we can infer +HIF1α may play a role in the induction 
of senescence as a means for chemo resistance. The non-replicative state of senescence may be a pathway that 
cancer cells try to exploit in order to evade chemotherapeutic treatments. Chemotherapy works to target rapidly 
dividing cells, thus many patients lose their hair during treatment. The harsh chemicals in chemotherapeutic 
treatment often create a toxic environment around the tumor in order to kill it. The cancer cell may use various 
innate mechanisms in order to adapt and survive in the toxic environment. One of these innate mechanisms is the 
oxidative stress pathway. If the oxidative stress pathway is activated, the cell can enter into senescence and be 
removed from the replicative population. If a cancer cell that was once rapidly replicating suddenly ceases 
replication, the chemotherapeutic drugs may no longer target it. The development of chemo resistant tumors leads 
to a worse prognosis for the patient. From our results, we can infer that +HIF1α may play a role in the induction 
of senescence as a means for chemo resistance. 
 
In order to efficiently and reliably apply the current observations of genetic-phenotype association and the value 
of prediction models based on common low-penetrance alleles to the clinic, further validation and confirmation 
using larger sample collections are indispensable. More research on this topic must be done in order to fully 
understand the role that over expression of HIF1a has on the induction of senescence and how it relates to chemo 
resistance. Cancer continues to evolve and we must adapt and evolve along with it in order to one day find a 
viable treatment option.  
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